Ironwood Pharmaceuticals, Inc.: Constipation trials
The registry lists 11 Constipation studies with Ironwood Pharmaceuticals, Inc. as lead sponsor. 0 are open to participants now and 9 have results posted.
Phase 2 5Phase 3 5Phase 4 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)CompletedNCT03573908Phase 3Results posted
- A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)TerminatedNCT02837783Phase 4Results posted
- Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)CompletedNCT02559206Phase 2Results posted
- Trial of Linaclotide in Patients With Chronic Idiopathic ConstipationCompletedNCT02291679Phase 3Results posted
- Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)CompletedNCT00938717Phase 3Results posted
- An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With ConstipationCompletedNCT00730171Phase 3Results posted
- Trial of Linaclotide in Patients With Chronic ConstipationCompletedNCT00730015Phase 3Results posted
- Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)CompletedNCT00460811Phase 2Results posted
- Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic ConstipationCompletedNCT00402337Phase 2Results posted
- Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic ConstipationCompletedNCT00306748Phase 2
- Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBSCompletedNCT00258193Phase 2